Dernières nouvelles pour Guardant Health (NASDAQ:GH) Stock

GUARDANT HEALTH INC

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Inc

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

GOLD HART COPPER CORP by GOLD HART COPPER CORP.

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX Inc Ordinary Shares - Class A

Gores Holdings IX Inc

Gores Holdings IX Inc Units (1 Ord Class A & 1/3 War)

Gores Holdings IX Inc Warrants (31/01/2027)

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by Greenheart Gold Inc.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

A significant shift in tone from Nvidia CEO Jensen Huang last week sent a wave of optimism through the quantum computing sector, sparking a multi-day rally in stocks such as Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>). 
The rally continued into Monday&#8217;s session as investors digested the implications of the news.
What To Know: Speaking at Nvidia&#8217;s GTC Paris conference, Huang <a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy">declared</a> that quantum computing is reaching an &#8220;inflection point,&#8221; a stark reversal of his previously cautious stance. He noted that the industry is now &#8220;within reach&#8221; of applying the technology to solve complex real-world problems, shortening his timeline for its practical application. 
He also highlighted Nvidia&#8217;s commitment to the ecosystem, announcing the availability of its quantum algorithm stack on advanced hardware.
The <a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy">commentary</a> from the leader of the world&#8217;s most influential chipmaker has profound implications. In January, Huang's suggestion that practical quantum computing was decades away had cast a shadow over the sector.
Read Also: <a href="https://www.benzinga.com/markets/market-summary/25/06/45957968/palantir-hits-new-peak-amd-rallies-to-6-month-highs-whats-driving-markets-on-monday">Palantir Hits New Peak, AMD Rallies To 6-Month Highs: What&#8217;s Driving Markets On Monday?</a>
His newfound bullishness, however, has renewed investor confidence in the technology&#8217;s near-term commercial viability and the potential for a new phase of hybrid quantum-classical computing.
Price Action: QUBT shares closed Monday up 27.22% to $21.22. Data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> highlights a significant short interest, with 23.23% of the stock&#8217;s float sold short.
This high short interest suggests the rally may be intensified by a short squeeze, where traders betting against the stock are forced to buy shares, adding more fuel to the upward trend started by last week's sector-wide news.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45955190/amd-stock-is-soaring-monday-whats-going-on">AMD Stock Is Soaring Monday: What&#8217;s Going On?</a>
<h1 class="wp-block-heading">How To Buy QUBT Stock</h1>
By now, you're likely curious about how to participate in the market for Quantum Computing, be it to purchase shares or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
Photo: Shutterstock

News

Short Sellers

Movers

Tech

NVDA

QUBT

Quantum Computing (QUBT) Stock Is Rocketing Higher: What's Driving The Rally?

<a href="https://pr.report/bkg7">Laser Photonics Corporation</a> ("LPC" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading global industrial developer of<a href="https://pr.report/bkg8"> CleanTech Laser Systems</a> for laser cleaning and other applications, today announced that it has received an extension until the close of business on June 20, 2025, to submit its 10-K for the period ended December 31, 2024, and its 10-Q for the period ended March 31, 2025, or provide NASDAQ with a plan to regain compliance. The Company continues to work closely with its auditors to resolve the outstanding issues and file these reports as expeditiously as possible.

LASE

Laser Photonics Granted Extension Until June 20, 2025 To Submit To File 10-K And 10-Q Filings To Nasdaq

Mr. Cooper Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) has outperformed the market over the past 10 years by 4.81% on an annualized basis producing an average annual return of 15.82%. Currently, Mr. Cooper Gr has a market capitalization of $9.24 billion. 
Buying $100 In COOP: If an investor had bought $100 of COOP stock 10 years ago, it would be worth $437.45 today based on a price of $144.36 for COOP at the time of writing.
<h3>Mr. Cooper Gr's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750104918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

COOP

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

DEVS

DevvStream Corp. Announces Delay In Q1 Financial Reporting Due To Data Compilation Issues

The regulatory review process for the sale of Ambac Assurance Corporation and Ambac Assurance UK Limited to funds managed by Oaktree Capital Management, L.P. is nearing completion and a hearing is expected to be held in the third quarter. Claude LeBlanc, President and Chief Executive Officer of Ambac stated, "Although the transaction has exceeded the anticipated timelines, we remain actively engaged with Oaktree in efforts to close the transaction as soon as possible."
To maintain financial flexibility during this transitional period, Ambac entered into an amendment to its $150 million credit facility with UBS, extending its maturity date to December 31, 2025. Further details of the amendment to the credit facility will be contained in a Current Report on Form 8-K to be filed with the SEC today.

General

AMBC

Ambac Financial Group Issues Update On the Timing Of the Sale Of Its Legacy Financial Guarantee Business

WIIM

APPS

Digital Turbine shares are trading higher after reporting better-than-expected Q4 EPS and sales.

Partnership brings speed, personalization, and automation to home lending
PHH Mortgage, one of the largest mortgage servicers in the U.S., and a subsidiary of Onity Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONIT#NYSE">ONIT</a>), is expanding its partnership with Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) to deliver faster, more seamless refinance and home equity experiences for borrowers.
PHH Mortgage has expanded its use of Blend&#39;s technology platform, already powering its mortgage lending operations, to now include Rapid Refi and Rapid Home Equity. As part of its ongoing digital transformation, the move will help PHH meet rising borrower expectations and deepen relationships across the homeownership journey, from mortgage origination to refinancing and home equity lending.
Both refinance and home equity are particularly important opportunities for loan servicers in today&#39;s market.
&quot;Many homeowners today are still paying elevated mortgage rates or sitting on untapped home equity,&quot; said Colin Friday, Senior Vice President of Consumer Lending at PHH Mortgage. &quot;As interest rates shift, many of these borrowers are actively exploring ways to improve their financial position&mdash;whether refinancing to lower monthly payments or using equity for major expenses. Blend&#39;s Rapid Home Lending suite helps us meet them in those key moments with a fast, intuitive experience that reduces fallout and builds lasting loyalty.&quot;
With Blend&#39;s digital banking platform at the core, the Rapid suite of solutions are designed for speed, personalization, and efficiency, helping PHH to streamline operations and stay ahead of the next wave of lending demand. Together, they unlock new capabilities that will enable PHH to:
<ul>
<li>Increase automation and operational efficiency across loan teams through deep data connectivity that pre-fills borrower information and eliminates manual steps&mdash;turning a traditionally tedious process into a seamless digital experience.</li>
<li>Improve ease of use for borrowers by surfacing personalized, pre-qualified offers at the start of the journey&mdash;so customers know exactly what options are available without having to dig.</li>
<li>Strengthen customer retention and recapture by meeting borrower expectations for speed and simplicity, reducing fallout, and reinforcing PHH&#39;s role as a trusted financial partner in every stage of homeownership.</li>
</ul>
&quot;PHH Mortgage&#39;s adoption of Rapid Refi and Rapid Home Equity reflects the growing momentum among top-tier servicers who are prioritizing retention and digital transformation,&quot; said Nima Ghamsari, co-founder and CEO of Blend. &quot;This moment in the industry marks a fundamental shift. Servicers are no longer just managing loans, they&#39;re investing in long-term customer relationships. And in today&#39;s market, speed matters more than ever. Borrowers are rate shopping in real time, and lenders have only minutes, not days, to engage them. The institutions that move fast and deliver seamless, personalized experiences will be the ones that win.&quot;

Contracts

BLND

ONIT

Onity Group's PHH Mortgage Enters Partnership With Blend To Enhance Refinance And Home Equity Experiences For Borrowers

ALGT

Allegiant Travel Entered Into $144M Credit Facility To Be secured By Boeing 737 MAX Aircraft Expected To Deliver To Company

U.S. Steel Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares rallied Monday after President Donald Trump approved the company&#8217;s takeover by Japan's Nippon Steel. 
The deal faced opposition and multiple reviews. It&#8217;s now clear to close after both firms committed to a series of measures designed to <a href="https://www.benzinga.com/markets/equities/25/06/45938248/trump-approves-nippon-steels-14-9-billion-bid-for-us-steel">protect U.S. interests.</a>
Read Next:<a href="https://www.benzinga.com/news/retail-sales/25/06/45953480/alibaba-pdd-stocks-climb-chinas-retail-sector-gains-despite-us-tariffs?utm_source=articleShare"> Alibaba, PDD Stocks Climb As China&#8217;s Retail Sector Gains Despite US Tariffs</a>
The Details: President Trump signed an executive order approving the merger after both companies agreed to a national security arrangement with the U.S. government, per <a href="https://www.cnbc.com/2025/06/16/us-steel-rallies-as-trump-approves-nippon-takeover.html">CNBC</a>.
The agreement includes provisions such as a "golden share" for the U.S. government, giving it special oversight powers over the company's operations. 
Both companies also stated that the deal would allow U.S. Steel to operate as a wholly owned subsidiary of Nippon North America, while maintaining commitments to domestic manufacturing and governance. 
"All regulatory approvals required for the completion of the Transaction have been received," U.S. Steel said in an SEC filing on Monday. "The Transaction remains subject to the satisfaction of customary closing conditions, and is expected to be completed promptly."
Why It Matters: The approval of Nippon's acquisition of U.S. Steel represents a major change for the industry. In early January, then-President Joe Biden <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">blocked the deal</a>, citing foreign ownership would threaten national security and <a href="https://www.whitehouse.gov/briefing-room/statements-releases/2025/01/03/statement-from-president-joe-biden-13/#:~:text=As%20I%20have%20said%20many,critical%20for%20resilient%20supply%20chains" target="_blank" rel="noreferrer noopener">undermine critical supply chains</a>.
Trump returned to office and also opposed the deal over security concerns.
To secure the deal, Nippon Steel committed to investing $14 billion, including up to $4 billion for a new mill. The investment was part of a broader strategy to address the Trump administration's concerns and gain approval.
Additionally, Trump doubled tariffs <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45873964/steel-stocks-slide-on-potential-us-mexico-tariff-deal-report">on imported steel </a>to 50% to protect domestic jobs, while supporting the sale of U.S. Steel to Nippon, in order to help revitalize the U.S. steel industry.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45851086/these-are-the-3-hottest-stock-market-themes-trending-now?utm_source=articleShare">These Are The 3 Hottest Stock Market Themes Trending Now</a></li>
</ul>
Image: Shutterstock

Global

US Steel Stock Rallies After Trump Approves Nippon Steel Deal

Spyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results.

Biotech

SYRE

Spyre Therapeutics To Announce Interim Phase 1 SPY002 Trial Results For IBD On June 17, 2025, With Conference Call And Webcast At 8:00am ET

Earnings

STRM

Streamline Health Solns Q1 EPS $(0.40) Up From $(0.75) YoY, Sales $4.81M Up From $4.33M YoY

Globus Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 600 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $8.60 million which missed the analyst consensus estimate of $12.00 million by 28.33 percent. This is a 11.50 percent increase over sales of $7.71 million the same period last year.

Earnings Misses

GLBS

Globus Maritime Q1 EPS $(0.07) Misses $(0.03) Estimate, Sales $8.60M Miss $12.00M Estimate

Southwest Gas Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) ("Southwest Gas Holdings" or the "Company") today announced the commencement of an underwritten secondary public offering of&nbsp;Centuri Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) ("Centuri") common stock (the "Offering"), pursuant to which&nbsp;Southwest Gas Holdings, as the selling stockholder, is offering 9,500,000 existing shares of Centuri's common stock.&nbsp;Southwest Gas Holdings&nbsp;expects to grant the underwriters a 30-day option to purchase up to an additional 1,425,000 shares of Centuri's common stock.

Offerings

CTRI

Southwest Gas Holdings Launches Secondary Offering Of 9.5M Centuri Shares

SLRX

Salarius Pharmaceuticals shares are trading higher after the company disclosed it received an extension from the Nasdaq to regain compliance.

Nasdaq Grants Salarius Pharmaceuticals Extension To Regain Compliance

Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) sees FY2026 sales of $515.000 million-$525.000 million vs $519.64 million analyst estimate.

Guidance

Digital Turbine Sees FY2026 Sales $515.000M-$525.000M vs $519.64M Est

Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) reported quarterly losses of $(0.48) per share. This is a 68.83 percent increase over losses of $(1.54) per share from the same period last year. The company reported $8.78 million in sales this quarter. This is a 56.39 percent decrease over sales of $20.14 million the same period last year.

Zeo Energy Q1 EPS $(0.48) Up From $(1.54) YoY, Sales $8.78M Down From $20.14M YoY

Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.04 by 150 percent. This is a 16.67 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $119.15 million which beat the analyst consensus estimate of $116.64 million by 2.16 percent. This is a 6.17 percent increase over sales of $112.22 million the same period last year.

Earnings Beats

Digital Turbine Q4 Adj. EPS $0.10 Beats $0.04 Estimate, Sales $119.15M Beat $116.64M Estimate

RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 600 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $18.90 million which beat the analyst consensus estimate of $17.24 million by 9.64 percent. This is a 17.32 percent increase over sales of $16.11 million the same period last year.

RFIL

RF Industries Q2 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $18.90M Beat $17.24M Estimate

High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 40 percent. The company reported quarterly sales of $96.94 million which beat the analyst consensus estimate of $96.73 million by 0.22 percent. This is a 5.83 percent increase over sales of $91.60 million the same period last year.

HITI

High Tide Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $96.94M Beat $96.73M Estimate

Press Releases

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Guardant Health

Actualités

Dernières nouvelles pour Guardant Health (NASDAQ:GH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL